yemenjmedYemen Journal of MedicinecoVolume 2 Issue 3MultidisciplinaryEnglishSeptember-DecemberNNY20231219ArticleUpdates on the pathophysiology and therapies of chylous pleural effusion: A narrative reviewEnglishY145150ElmukhtarHabasEnglishNKalifaFarfarEnglishYAlmehdiErrayesEnglishYGamalAlfitoriEnglishYHafedhGhazouaniEnglishYAlaHabasEnglishYAmnnaRayniEnglishYAishaAladabEnglishY10.32677/yjm.v2i3.4330Chylous pleural effusion (CPE) is a milky pleural fluid that contains high levels of proteins, cholesterol, triglycerides, or chylomicrons. The main cause of CPE is disruption of the thoracic duct caused by traumatic or non-traumatic causes. High triglyceride, cholesterol, and/or chylomicron levels confirm the diagnosis. Recognizing the chyle leak site and underlying etiology is critical to the management of this clinical condition. There is no specific consensus on chylothorax treatment. However, a multidisciplinary (medical, surgical, and oncological) team approach is recommended.EnglishChylous pleural effusion, Epidemiology of chylous effusion, Pathophysiology pf chylous pleural effusion, Managementof chylous pleural effusionhttps://yemenjmed.com/admin/abstract?id=77References16191. Yalcin NG, Choong CK, Eizenberg N. Anatomy and pathophysiology of the pleura and pleural space. Thorac Surg Clin 2013;23:1-10, v.2. Yousaf Z, Ata F, Chaudhary H, et al. Etiology, pathological characteristics, and clinical management of black pleural effusion: A systematic review. Medicine (Baltimore) 2022;101:e28130.3. Villena V, Land;oacute;pez-Encuentra A, Garcand;iacute;a-Lujand;aacute;n R, et al. Clinical implications of appearance of pleural fluid at thoracentesis. Chest 2004;125:156-9.4. Riley LE, Ataya A. Clinical approach and review of causes of a chylothorax. Respir Med 2019;157:7-13.5. Huggins JT. Chylothorax and cholesterol pleural effusion. Semin Respir Crit Care Med 2010;31:743-50.6. Maldonado F, Cartin-Ceba R, Hawkins FJ, et al. Medical and surgical management of chylothorax and associated outcomes. Am J Med Sci 2010;339:314-8.7. Ur Rehman K, Sivakumar P. Non-traumatic chylothorax: Diagnostic and therapeutic strategies. Breathe (Sheff) 2022;18:210163.8. Bessone LN, Ferguson TB, Burford TH. Chylothorax. Ann Thorac Surg 1971;12:527-50.9. McGrath EE, Blades Z, Anderson PB. Chylothorax: Aetiology, diagnosis and therapeutic options. Respir Med 2010;104:1-8.10. Cholet C, Delalandre C, Monnier-Cholley L, et al. Nontraumatic chylothorax: Nonenhanced MR lymphography. Radiographics 2020;40:1554-73.11. Sequeira M, Nogueira F, Pestana Santos C, et al. A rare case of a chylous pleural effusion as the initial manifestation of synchronous tumors. Cureus 2023;15:e46903.12. Majdalany BS, Murrey DA Jr., Kapoor BS, et al. ACR appropriateness criteriaand;reg; chylothorax treatment planning. JAm Coll Radiol 2017;14:S118-26.13. Rudrappa M, Paul M. Chylothorax. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/ books/nbk459206 [Last accessed on 2023 Feb 21].14. Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009;84:129-33.15. Doerr CH, Miller DL, Ryu JH. Chylothorax. Semin Respir Crit Care Med 2001;22:617-26.16. Al-Gahmi A, Alhuthali M, Alrehaili M, et al. Unusual synchronous association of solid tumors with hematological malignancies in multiple primary cancers: Case series and literature review. Case Rep Oncol 2021;8:352-64.17. Pan SY, Huang CP, Chen WC. Synchronous/metachronous multiple primary malignancies: Review of associated risk factors. Diagnostics (Basel) 2022;11:1940.18. Villena V, de Pablo A, Martand;iacute;n-Escribano P. Chylothorax and chylous ascites due to heart failure. Eur Respir J 1995;8:1235-6.19. Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980;55:700-4.20. Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg 2007;32:362-9.21. Maldonado F, Ryu JH. Yellow nail syndrome. Curr Opin Pulm Med 2009;15:371-5.22. Agrawal V, Doelken P, Sahn SA. Pleural fluid analysis in chylous pleuraland;nbsp;effusion. Chest 2008;133:1436-4123. Furukawa M, Hara A, Miyazaki R, et al. Assessment of fat-free diet for postoperative chylothora. Kyobu Geka 2018;713:1063-5.24. Yang RF, Liu TT, Wang P, et al. Ligation of thoracic duct during thoracoscopic esophagectomy can lead to decrease of T lymphocyte. J Cancer Res Ther 2018;14:1535-9.25. Pospiskova J, Smolej L, Belada D, et al. Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. Orphanet J Rare Dis 2019;14:9.26. Papoulidis P, Vidanapathirana P, Dunning J. Chylothorax, new insights in treatment. J Thorac Dis 2018;10:S3976-7.27. Takuwa T, Yoshida J, Ono S, et al. Low-fat diet management strategy for chylothorax after pulmonary resection and lymph node dissection for primary lung cancer. J Thorac Cardiovasc Surg 2013;146:571-4. 28. Selle JG, Snyder WH 3rd, Schreiber JT. Chylothorax: Indications for surgery. Ann Surg 1973;177:245-9.29. Jensen GL, Mascioli EA, Meyer LP, et al. Dietary modification of chyle composition in chylothorax. Gastroenterology 1989;97:761-5.30. Jimenez CA, Mhatre AD, Martinez CH, et al. Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. Chest 2007;132:1584-90.31. Bhatnagar R, Maskell NA. Indwelling pleural catheters. Respiration 2014;88:74-85.32. Achildi O, Smith BP, Grewal H. Thoracoscopic ligation of the thoracic duct in a child with spontaneous chylothorax. J Laparoendosc Adv Surg Tech A 2006;16:546-9.33. Tang H, Bai Y, Shen W, et al. Anastomosis of the thoracic duct and the azygos vein for the treatment of recurrent chylothoraxes. Eur J Cardiothorac Surg 2018;53:1093-4.34. Matsumoto T, Yamagami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. Br Jand;nbsp;Radiol 2009;82:286-90.35. Binkert CA, Yucel EK, Davison BD, et al. Percutaneous treatment of highoutput chylothorax with embolization or needle disruption technique. J Vasc Interv Radiol 2005;16:1257-62.36. Kilic D, Sahin E, Gulcan O, et al. Octreotide for treating chylothorax after cardiac surgery. Tex Heart Inst J 2005;32:437-9.37. Sharkey AJ, Rao JN. The successful use of octreotide in the treatment of traumatic chylothorax. Tex Heart Inst J 2012;39:428-30.38. Habuka M, Ito T, Yoshizawa Y, et al. Usefulness of a pleuroperitoneal shunt for treatment of refractory pleural effusion in a patient receiving maintenance hemodialysis. CEN Case Rep 2018;7:189-94.39. Gerstein J, Kofahl-Krause D, Frand;uuml;hauf J, et al. Complete remission of a lymphoma-associated chylothorax by radiotherapy of the celiac trunk and thoracic duct. Strahlenther Onkol 2008;184:484-7.40. Van De Voorde L, Vanneste B, Borger J, et al. Rapid decline of follicular lymphoma-associated chylothorax after low dose radiotherapy to retroperitoneal lymphoma localization. Case Rep Hematol 2014;2014:684689.41. Milsom JW, Kron IL, Rheuban KS, et al. Chylothorax: An assessment of current surgical management. J Thorac Cardiovasc Surg 1985;89:221-7.42. Lampson RS. Traumatic chylothorax; a review of the literature and report of a case treated by mediastinal ligation of the thoracic duct. J Thorac Surg 1948;17:778-91.